Melbourne, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), ("Amplia" or the "Company"), is pleased to announce the appointment of Mr Brett Carter to the Board of Directors as non-executive director, effective from 6 July 2026.
Amplia Board chair Ms Jane Bell AM commented, "I am delighted to welcome Brett to the Board at this exciting time in the Company's development. His extensive experience in the structuring and negotiation of licensing, acquisition, investment and financing transactions across global pharmaceutical markets will be critical as Amplia's lead drug narmafotinib progresses into later stage development."
Mr Carter is an experienced biopharmaceutical executive with more than 25 years' global experience across oncology drug development, corporate strategy and business development. Mr Carter spent 11 years with GSK in London, including as a director in the company's global corporate transactions team, where he led and supported major licensing, acquisition, investment and divestment transactions across Europe, Asia and the United States. Mr Carter was subsequently CEO of the Cancer Therapeutics Cooperative Research Centre, where Amplia's drug assets were discovered, and while there was involved in the licensing of an oncology program to Pfizer in a deal valued up to $670 million.
Mr Carter holds an MBA from London Business School and a BSc from RMIT University and is a graduate of the Australian Institute of Company Directors. He is currently COO of Melbourne-based Medicines Development for Global Health, a director of privately-held biotech Greywolf Therapeutics Australia, and strategic adviser to various Australian life science companies.
This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.
Investor Contact: | Media Contact: |
About Amplia Therapeutics Limited